In the phase III HM-APOLLO-301 and HM-APOLLO-302 trials in adults with mild-to-moderate hypertension, a single-pill ultra-low-dose triple combination of amlodipine/losartan/chlorthalidone produced similar systolic BP lowering to 5 mg amlodipine and greater lowering than 50 mg losartan over 8 weeks, with similar short-term tolerability. In Study 301, the combo met noninferiority vs amlodipine for systolic BP reduction at week 8, with an upper bound of the 1-sided 97.5% CI of 2.8 mm Hg.

Why It Matters To Your Practice

• These are phase III, double-blind, active-controlled data for an initial single-pill, ultra-low-dose triple therapy strategy in Hypertension (HTN).

• For patients with mild-to-moderate HTN, the regimen offers a validated alternative to starting with standard-dose monotherapy alone.

• A single-pill approach may also support adherence by simplifying treatment from the outset.

Clinical Benefits

• The triple low-dose pill matched amlodipine for systolic BP reduction at 8 weeks.

• It outperformed losartan monotherapy for BP lowering over the same period.

• Using 3 agents at ultra-low doses may help achieve BP control while limiting dose-related adverse effects seen with higher-dose single agents.

Managing Risks

• Short-term tolerability was similar to comparator monotherapy, but the trials only followed patients for 8 weeks.

• Monitor for expected effects from each component, including edema, dizziness, electrolyte abnormalities, and renal function changes.

• As with any combination antihypertensive regimen, patient selection, baseline labs, and follow-up BP checks remain important.

The Bottom Line

• For adults with mild-to-moderate HTN, this single-pill ultra-low-dose triple combination appears to be an effective, well-tolerated initial option.

• It gives clinicians another evidence-based path when monotherapy may be less likely to achieve early BP control.